Xencor

Historical price data

Xencor's mission is to expand the therapeutic boundaries of monoclonal antibodies through its industry-leading XmAb® Fc engineering platform. The company has achieved significant validation through strategic collaborations with major pharmaceutical firms like Novartis and Amgen, and three partnered drugs are commercially available. Xencor's strategy leverages a lean, capital-efficient model, focusing internal resources on a diversified pipeline of over 20 clinical-stage programs while generating substantial partnership revenue and optionality.

XmAb® Protein Engineering Platform: A modular system for rational design of antibody Fc domains to enhance half-life (Xtend™), cytotoxicity, and enable stable bispecific antibody formats through minimal amino acid changes.